Msh6 44

Manufactured by Roche

Sourced in United States

MSH6 (44) is a laboratory equipment product from Roche. It serves a core function, but a detailed description cannot be provided while maintaining an unbiased and factual approach without extrapolation.

Automatically generated - may contain errors

Lab products found in correlation

Mlh1 m1, by Roche (3 mentions) Msh2 g219 1129, by Roche (3 mentions) Pms2 epr 3947, by Roche (3 mentions) Ventana benchmark autostainer, by Roche (2 mentions) Autostainer link 48, by Agilent Technologies (1 mentions) Ventana benchmark xt system, by Roche (1 mentions) Epr3947, by Roche (1 mentions) Dp72 microscope, by Olympus (1 mentions) Epr3947, by Cell Marque (1 mentions)

Spelling variants of this product

-MSH6 (clone 44, (8 citations)

5 protocols using msh6 44

Immunohistochemical Analysis of MMR Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

Four 3‐μm‐thick sections of FFPE samples were made for IHC analysis and stored at 37°C overnight. We used two auto‐staining systems. Protein expression was evaluated with mutL homolog 1 (MLH1) (M1; Ventana Medical Systems; Roche Group), mutS homolog 2 (MSH2) (G219‐1129; Ventana Medical Systems), mutS homolog 6 (MSH6) (44; Ventana Medical Systems), and postmeiotic segregation 1 homolog 2 (PMS2) (EPR3947; Ventana Medical Systems) antibodies using the Ventana BenchMark XT system (Roche). Protein expression was evaluated with MLH1 (ES05; Agilent), MSH2 (FE11; Agilent), MSH6 (EP49; Agilent), and PMS2 (EP51; Agilent) antibodies using the Autostainer Link48 (Agilent).²⁷, ²⁸ All sections were evaluated by a medical technologist (K.A.) and a pathologist (T.O). Tumors with completely absent nuclear staining of at least one of MLH1, MSH2, MSH6, or PMS2 were classified as dMMR.

Amemiya K., Hirotsu Y., Nagakubo Y., Watanabe S., Amemiya S., Mochizuki H., Oyama T., Kondo T, & Omata M. (2022). Simple IHC reveals complex MMR alternations than PCR assays: Validation by LCM and next‐generation sequencing. Cancer Medicine, 11(23), 4479-4490.

+ Open protocol

+ Expand

Immunohistochemical Analysis of DNA Mismatch Repair Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

We examined protein expression for MLH1, MSH2, PMS2 and MSH6 in 28 tumor tissues by immunohistochemical staining as described previously²⁴ (link) using following antibodies (MLH1 (M1); MSH2 (G219-1129); PMS2 (EPR3947); MSH6 (44) [Ventana, AZ, USA]). The stained slides were analyzed by a pathologist. Images were captured using Olympus DP72 microscope (Olympus, Tokyo, Japan) with a 20X objective lens.

Jamaluddin M.F., Ko Y.A., Ghosh A., Syed S.M., Ius Y., O’Sullivan R., Netherton J.K., Baker M.A., Nahar P., Jaaback K, & Tanwar P.S. (2022). Proteomic and functional characterization of intra-tumor heterogeneity in human endometrial cancer. Cell Reports Medicine, 3(9), 100738.

+ Open protocol

+ Expand

Immunohistochemistry for Mismatch Repair Deficiency

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on formalin-fixed and paraffin-embedded tumor sections cut at 4-micron thickness and stained on a Ventana Bench Mark Autostainer (Ventana Medical System, Tucson, Arizona). The following rabbit monoclonal primary antibodies were used: MLH-1 (M1Ventana), PMS2 (EPR 3947, Ventana), MSH2 (G219-1129, Ventana), and MSH6 (44, Ventana). Antibodies were pre-diluted by the manufacturer and staining was performed following the manufacturer’s protocols in collaboration with platform vendors. Technical methodologies and quality assurance were performed at the Immunopathology Laboratory of Long Island Jewish Medical Center (Northwell Health System, New Hyde Park, NY). Complete loss of any of the foregoing markers lead to the designation of MMR deficient.

Hacking S., Wu D., Nasim R., Chavarria H, & Nasim M. (2021). Nature and significance of stromal differentiation in carcinosarcoma (MMMT): unravelling the biology and shifting current paradigms. Rare Tumors, 13, 20363613211010876.

+ Open protocol

+ Expand

Immunohistochemical Evaluation of MMR Status

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed in order to determine MMR status on formalin-fixed and paraffin-embedded tumor sections cut at 4-μM thickness and stained on a Ventana Bench Mark Autostainer (Ventana Medical System, Tucson, AZ). The following rabbit monoclonal pre-diluted primary antibodies were used: MLH-1(M1, Ventana), PMS2 (EPR 3947, Ventana), MSH2(G219-1129, Ventana), and MSH6 (44, Ventana). Technical methodologies and quality assurance were undertaken by certified histotechnologists at the immunohistochemical laboratory of Long Island Jewish Medical Center (Northwell Health System, New Hyde Park, NY). Cases showing loss of immunohistochemical staining (<1%) for any of the following stains: MLH1, PMS2, MSH2, and MSH6 were considered MMR-deficient.

Hacking S.M., Wu D., Alexis C, & Nasim M. (2022). A Novel Superpixel Approach to the Tumoral Microenvironment in Colorectal Cancer. Journal of Pathology Informatics, 13, 100009.

+ Open protocol

+ Expand

Evaluating MMR Protein Expression in FFPE Tissues

Check if the same lab product or an alternative is used in the 5 most similar protocols

The expression of MMR proteins (MLH1, MSH2, MSH6, and PMS2) in formalin-fixed, paraffin-embedded (FFPE) tissues from CRCs, ECs, and sarcomas was evaluated using standardized IHC protocols applied in the clinical routine at the Anatomic Pathology Department of ACCCC. The following antibodies were used: MLH1 (M1; Ventana), MSH2 (G219-1129; Cell Marque), MSH6 (44; Ventana), and PMS2 (EPR3947; Cell Marque). Loss of nuclear expression was considered when tumor cells showed complete absence of expression for one or more markers, with adequate positive internal control in stromal or inflammatory cells.

de Angelis de Carvalho N., Niitsuma B.N., Kozak V.N., Costa F.D., de Macedo M.P., Kupper B.E., Silva M.L., Formiga M.N., Volc S.M., Aguiar Junior S., Palmero E.I., Casali-da-Rocha J.C., Carraro D.M, & Torrezan G.T. (2020). Clinical and Molecular Assessment of Patients with Lynch Syndrome and Sarcomas Underpinning the Association with MSH2 Germline Pathogenic Variants. Cancers, 12(7), 1848.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!